Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively ...